Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW – Get Free Report) saw a large drop in short interest in June. As of June 30th, there was short interest totaling 3,709 shares, a drop of 77.6% from the June 15th total of 16,531 shares. Based on an average daily trading volume, of 53,981 shares, the short-interest ratio is presently 0.1 days.
Rocket Pharmaceuticals Stock Performance
NASDAQ:RCKTW remained flat at $0.00 during mid-day trading on Friday. The business’s 50 day moving average is $0.01 and its 200-day moving average is $0.01. Rocket Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $0.08.
About Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.
Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW.
Featured Stories
- Five stocks we like better than Rocket Pharmaceuticals
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
